Loading...
Cogent Biosciences Q1 2025 Earnings Report
Estimated EPS:-$0.58
16.0% YoY
Key Takeaways
Cogent Biosciences reported a net loss of $72.0 million for the first quarter of 2025, an increase from $58.3 million in the same period last year. The company ended the quarter with $245.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2026, including key clinical trial readouts.
Net loss for Q1 2025 was $72.0 million, compared to $58.3 million for Q1 2024.
Cash, cash equivalents, and marketable securities totaled $245.7 million as of March 31, 2025.
Research and development expenses increased to $63.0 million in Q1 2025 from $52.7 million in Q1 2024, driven by ongoing clinical trials.
General and administrative expenses rose to $11.9 million in Q1 2025 from $9.7 million in Q1 2024 due to organizational growth.
Forward Guidance
Cogent Biosciences anticipates significant clinical trial readouts in 2025 and expects its current cash reserves to fund operations into late 2026, supporting a potential launch of bezuclastinib in 2026.
Positive Outlook
- SUMMIT top-line results in NonAdvanced SM expected in July 2025.
- APEX top-line results in Advanced SM expected in the second half of 2025.
- PEAK top-line results in GIST expected by end of 2025.
- Sufficient cash to fund operations into late 2026, including through clinical readouts.
- Potential commercial launch of bezuclastinib in 2026.
Challenges Ahead
- Forward-looking statements are subject to risks and uncertainties, and actual results may differ.
- No guarantee that forecasts or milestones will be achieved.
- New risks and uncertainties may emerge over time.
- The company does not undertake to publicly update or revise forward-looking statements.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...